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Abstract
LEDGF/p75 interacts with DNA/protein to regulate gene expression and function. Despite the recognized diversity of
function of LEDGF/p75, knowledge of its transregulation is in its infancy. Here we report that LEDGF/p75 gene is TATA-less,
contains GC-rich cis elements and is transcriptionally regulated by Sp1 involving small ubiquitin-like modifier (Sumo1). Using
different cell lines, we showed that Sp1 overexpression increased the level of LEDGF/p75 protein and mRNA expression in a
concentration-dependent fashion. In contrast, RNA interference depletion of intrinsic Sp1 or treatment with artemisinin, a
Sp1 inhibitor, reduced expression of LEDGF/p75, suggesting Sp1-mediated regulation of LEDGF/p75. In silico analysis
disclosed three evolutionarily conserved, putative Sp1 sites within LEDGF/p75 proximal promoter (2170/+1 nt). DNA-
binding and transactivation assays using deletion and point mutation constructs of LEDGF/p75 promoter-CAT revealed that
all Sp1 sites (250/243, 2109/2102 and 2146/2139) differentially regulate LEDGF/p75. Cotransfection studies with Sp1 in
Drosophila cells that were Sp1-deficient, showed increased LEDGF/p75 transcription, while in lens epithelial cells (LECs)
promoter activity was inhibited by artemisinin. These events were correlated with levels of endogenous Sp1-dependent
LEDGF/p75 expression, and higher resistance to UVB-induced cell death. ChIP and transactivation assays showed that
Sumoylation of Sp1 repressed its transcriptional activity as evidenced through its reduced binding to GC-box and reduced
ability to activate LEDGF/p75 transcription. As whole, results revealed the importance of Sp1 in regulating expression of
LEDGF/p75 gene and add to our knowledge of the factors that control LEDGF/p75 within cellular microenvironments,
potentially providing a foundation for LEDGF/p75 expression-based transcription therapy.
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Introduction
Gene expression is transcriptionally regulated through the
interaction between trans-acting factors and the cis-elements of gene-
specific promoters. A nuclear protein discovered relatively
recently, LEDGF/p75 affects a variety of functions involved with
cellular survival and development of cellular abnormalities
[1,2,3,4]. The functions of LEDGF/p75 protein are related to
its expression level. Studies in cultured cell lines as well as in vivo
have shown that overexpression of LEDGF/p75 gives growing
cells a selective survival advantage by blocking death pathways
[5,6,7]. LEDGF/p75 provides cytoprotection by acting as a
transregulator of stress-associated genes such as Hsp27, -25, and -
90, and aB-crystallin [8]. However, overexpression of LEDGF/
p75 has been shown to be involved in subcutaneous angiogenesis
and lymphangiogenesis of ovarian carcinoma tumors [9], and
aberrant expression of LEDGF/p75 has been reported in 61% of
prostate tumors [10]. These studies suggest that the level of
LEDGF/p75 expression can determine the fate of cells in various
cellular microenvironments.
LEDGF/p75 was originally identified as a transcriptional co-
activator and transactivator that localizes predominantly in
nucleus and binds to chromatin [11]. It performs various functions
by interacting with protein/DNA [12]. LEDGF/p75 shares the
first 325 amino acids with p52, an alternative splice variant from
the same gene, mapping to chromosome 9p22.3 genetic locus
[11,13]. LEDGF/p75 is a multi-domain flexible nuclear protein.
Reports indicate that PWWP and A/T hook domains of N-
terminal LEDGF/p75 are involved in tethering of the lentiviral
preintegration complex and chromatin [12]. C-terminal of
LEDGF/p75 containing the integrase binding domain (IBD;
residues 347 to 429) [14] binds to integrase and facilitates HIV
integration with chromosome. Recently LEDGF/p75 has been
shown to interact with multiple proteins such as Myc-interacting
protein JPO2 [14] and mixed-lineage leukemia (MLL)/menin
complex [15], a domesticated transposase PogZ (pogo transpos-
able element derived protein with zinc finger) [14], Cdc7-activator
of S-phase kinase (ASK) [16], and methyl CpG Binding Protein
MeCP2 [17]. LEDGF/p75 protein has been shown to be a
substrate of Sumo (small ubiquitin-like modifier), and Sumoylation
of LEDGF/p75 negatively regulates its half-life and transcriptional
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(amino acids 421–442 and amino acids 471–492) bind to heat
shock element (HSE, nGAAn) and regulate transcription of small
heat shock protein genes (hsps). N-terminal LEDGF/p75 has been
found to interact with stress-related response elements (STRE,
nA/TGGGGA/Tn), thereby regulating transcription
[2,5,8,19,20] and enhancing cell survival. Most importantly,
LEDGF/p75 binding is not restricted to HSE or STRE, but
LEDGF/p75 also binds to markers of active chromatin as well as
RNA polymerase II, and correlates with transcriptional activity of
the transcriptional unit [21]. More recently, LEDGF/p75 was
found to selectively bind to supercoiled DNA and to recruit its
binding partners to active transcription units [22]. Taken together,
these reports indicate wide-spectrum activity of LEDGF/p75, and
underscore its biological importance. The DNA-binding activity of
LEDGF/p75 appears to be attributable to cellular microenviron-
ment and cell background. During stress, LEDGF/p75 binds to
stress response element(s), while under normal physiological
conditions it interacts with chromatin/DNA.
Sp1, a prototypic C2H2-type zinc finger containing DNA
binding protein, can transactivate or repress transcription in
response to physiologic or pathologic stimuli. Recently, Sp1 was
shown to be a regulator of several genes implicated in controlling
many cellular phenomena including growth, [23], differentiation
[24], apoptosis [24], angiogenesis [24] and immune response [24].
The multicellular functions of Sp1 involve the action through
which it regulates gene transcription. Sp1 binds to GC-rich Sp1-
responsive element (GC-box) with greater affinity [24] and can
regulate TATA-less or TATA-containing gene promoter by direct
binding to GC box or protein-protein interactions or by recruiting
cofactors and other transcription factors. Many gene promoters
are known to be regulated by Sp1 [25,26,27], although studies of
model genes have revealed diverse mechanisms by which inducible
transcription can be regulated. In fact, Sp1 was originally known
as a constitutive activator of housekeeping genes, and recent
reports indicate that posttranslational modification of Sp1
regulates its transcriptional activity and integrity [28]. Studies
have shown that Sp1 undergoes Sumo1 conjugation [29], and that
Sumoylation of Sp1 reduces its transcriptional potential [29].
Sumoylation/desumoylation is a dynamic process that maintains
cellular signaling by conjugating or deconjugating Sumo1 to
protein substrate(s). Like DUBs (deubiquitinases) opposing ubiqui-
tination, members of the Sentrin/Sumo-specific proteases (Senp)
enzyme family remove Sumo conjugated substrate to control
protein function [30]. However, the potential effect of the Sp1
Sumoylation and desumoylation process on regulation of LEDGF/
p75 transcription remains unknown. It is also unclear whether Sp1
regulation influences LEDGF/p75 downstream target genes. In
previous studies, we found that LEDGF/p75 gene promoter
ranging from 2315 to +35 was sufficient for LEDGF/p75
promoter activity [20]. In the current study, a careful analysis of
the LEDGF/p75 promoter using bioinformatics tools showed that
the gene promoter was TATA-less and highly GC-rich and
contains three putative Sp1-responsive elements. Several other
regulatory elements predicted were heat shock and stress-response
elements, VDR/RXR (vitamin D receptor/retinoid X receptor),
STAT, E2F, OCT1, GRE, Sp1, GATA-1, IRF-1 and IRF-2,
including the TIE sites at 2444 to 2433 from the transcription
start site [20]. Furthermore, an extensive literature survey revealed
that Sp1 is largely associated with regulating TATA-less promoter
[31], and may be a transregulator of the LEDGF/p75 gene
promoter that lacks the canonical TATA box consensus
transcription. From the dynamic systems point of view, we also
studied how LEDGF/p75 expression is fine tuned by the
regulatory mechanism Sumoylation of Sp1, and how, at a critical
level, Sp1 activity is reversibly engaged in favor of cellular
integrity.
In this work, we report that Sp1 transactivates the human
LEDGF/p75 gene; in fact, the finding that Sp1 is a ubiquitous
transcriptional protein is consistent with the expression of LEDGF/
p75 gene in cells. We show that the 59-flanking region sequences of
the human LEDGF/p75 gene are devoid of CCAAT and TATA-
boxes, that is a TATA-less promoter and that the minimal
promoter is enriched with GC content. We have determined the
Transcription start site (TSS) and characterized GC-rich DNA
sequence motif in the promoter responsible for regulation of
LEDGF/p75 transcription. GC-rich transcriptional control ele-
ments are always complicated by the relatively large number of
DNA-binding proteins that are capable of interaction with GC-
rich sequences [32]. However, we were able to identify three Sp1-
responsive elements in the proximal region of LEDGF/p75
promoter and determine the function and contribution of each
Sp1 regulatory element in LEDGF/p75 gene transcription. Also,
we provide evidence that LEDGF/p75 transcription is controlled
by Sp1 posttranslational modification, Sumoylation/desumoyla-
tion. We found that Sp1 overexpression increased LEDGF/p75
mRNA and protein expression in cells, and these cells gained
resistance against UVB stress. Our studies revealed, for the first
time, the mechanism by which Sp1 regulates LEDGF/p75
expression. This regulation may be attributed to cell survival
response, by avoiding any aberrant expression of LEDGF/p75
that would cause cellular abnormalities.
Results
Sp1 expression-dependent abundance of LEDGF/p75
mRNA and protein in hLECs demonstrated that Sp1 may
be a regulator of LEDGF/p75
Both LEDGF/p75 and Sp1 are ubiquitously expressed and play
roles in controlling cellular survival, differentiation, and prolifer-
ation [3,4,24]. Their aberrant expression alters normal cellular
signaling, leading to cell abnormalities such as cancer and its
progression [3,10,15,24]. We envisaged that Sp1 might be a
regulator of LEDGF/p75 expression. We examined the relative
expression pattern of LEDGF/p75 and Sp1 protein and mRNA in
hLECs derived from eye lenses of subjects aged 16–75 years, and
divided them into three groups: (group 1, 16–26 y; group 2, 34–
42 y, and group 3, 52–75 y (Fig. 1A). Results revealed that the
changes in expression pattern of both molecules were sequentially
similar in all age groups tested. As shown in Fig. 1A, expression
levels of LEDGF/p75 mRNA (black bars) and Sp1 mRNA (gray
bars) were well correlated. We also examined protein level and
mRNA levels in LECs isolated from 24- and 64-year-old subjects,
and found that expression patterns of Sp1 mRNA (Fig. 1B) and
protein (Fig. 1C) directly correlated with expression levels of
LEDGF/p75 protein and mRNA. These data indicated that
changes in LEDGF/p75 expression pattern can be associated with
changes in Sp1 expression.
Next, to test whether LEDGF/p75 expression is indeed induced
by Sp1, we ectopically expressed human Sp1 by transfecting cells
with different concentrations of pCMV-Sp1 (0, 2, 4, 8 mg) or
pCMV-empty vector as described in the Materials and Methods
section. The extracted protein from transfectants was resolved by
SDS-gel electrophoresis and blotted onto nitrocellulose mem-
brane. To ascertain equal loading and relative expression levels of
LEDGF/p75, Sp1 and b-actin (internal control), we continued
with the same blotted membrane to probe or reprobe after
stripping with antibody specific to LEDGF/p75 or Sp1 or b-actin.
LEDGF/p75 Regulation by Sp1
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37012Figure 1. Expression pattern of LEDGF/p75 in LECs from human eye lenses of different ages was associated with Sp1 expression. A
and B, mRNA expression levels of LEDGF/p75 (black bars) and Sp1 (gray bars) were analyzed by real time PCR. Total RNA was isolated from LECs
separated from lenses of human subjects of different age groups and reverse transcribed cDNA was subjected to real time PCR analysis with specific
primers as detailed in Materials and Methods. Age group 1 (n=4, 16–26 years); Age group 2 (n=3, 34–42 years); Age group 3 (n=7, 52–75 years). n;
denotes number of subjects. The data represent the mean 6 S.D. from three independent experiments (** p,0.001). C, Western analysis of LEDGF/
p75 and Sp1 protein using their corresponding specific antibodies. hLECs isolated from eye lenses of 24- and 64-year-old human subjects were
cultured as described in Materials and Methods. Cellular proteins from confluent cells were extracted, and equivalent amounts were loaded onto SDS-
PAGE, transferred to a PVDF membrane and processed for immunoblotting. Western analysis showed the expression levels of LEDGF/p75 (upper
panel) and Sp1 (middle panel). Lower panel, membrane probed with b-actin antibody as loading/internal control. The same membrane was probed
and reprobed with antibodies following stripping and restriping to obtain relative expression of Sp1, LEDGF/p75 or b-actin. Each band of blot was
quantified using densitometer shown at the right. Images are representatives from three independent experiments. D and E, Sp1 upregulated
expression of LEDGF/p75 protein and mRNA in hLECs in dose dependent fashion. hLECs were transfected with either pCMV-vector or increasing
amounts of pCMV-Sp1 (2, 4 and 8 mg) as indicated and described in Materials and Methods section. Total Protein and RNA were extracted after 48 h
of transfection and were used for Western analysis (D) and real time PCR (E) respectively, using specific probes. D, left, Western analysis data showing
the expression levels of LEDGF/p75 (upper panel) in cells transfected with plasmid encoding Sp1 at different concentrations (middle panel). Lower
panel, membrane probed with b-actin antibody. The same membrane was probed and reprobed with antibodies following stripping and restriping to
obtain relative expression of Sp1, LEDGF/p75 or b-actin. Right, Histogram displaying relative protein band density indicated as values 6 S.D. of three
independent experiments. E, Histogram showing the values (mean 6 S.D.) of Sp1 concentration-dependent expression of LEDGF/p75 mRNA (black
bars vs gray bars) obtained from three independent experiments (**p,0.001). F, A Sp1 inhibitor, artemisinin, reduced expression of LEDGF/p75 in
LECs in dose-dependent manner. Cultured cells were treated with either increasing concentrations of artemisinin (50, 150 and 300 mM) or with vehicle
control. Cell lysates were resolved onto SDS-PAGE and analyzed by Western blot for the effects of artemisinin on expression of LEDGF/p75 and Sp1
protein. Relative band density in pixels is shown below the Western blot images (*p,0.01, **p,.001). b-actin was used as internal control. G and H,
Representative immunoblots showing depletion of Sp1 using Sp1 Knockdown assay. Sp1-specific shRNA constructs were transiently (G) and stably (H)
transfected as described in Materials and Methods section. Protein lysate was prepared and Western analysis was carried out. The same membrane
was probed and reprobed with antibodies following stripping and restriping to obtain relative expression of Sp1 or LEDGF/p75 or b-actin. Relative
band density in pixels is shown below the Western blot images (**p,.001).
doi:10.1371/journal.pone.0037012.g001
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sion of LEDGF/p75 protein (Fig. 1D, upper image), and expression
of LEDGF/p75 was dependent on Sp1 concentration (Fig. 1D,
middle image). The same blotted membrane immunostained with
b-actin antibody did not reveal any altered expression in b-actin
(Fig. 1D, lower image), suggesting that LEDGF/p75 protein was
selectively and specifically increased by Sp1. We next examined
whether cells with higher levels of Sp1 displayed higher LEDGF/
p75 mRNA. As described above, Sp1 transfectants containing
different concentrations of Sp1 plasmid were harvested. RNA
isolated from these cells was processed for real-time PCR. The
expression levels of LEDGF/p75 mRNA were significantly
increased in cells overexpressing Sp1, and the increases were
dependent on Sp1 expression (Fig. 1E, black bars vs gray bars).
Collectively, these observations revealed that Sp1 overexpression
enhanced the expression of LEDGF/p75 mRNA in hLECs, and
we found a significant direct correlation between Sp1 and
LEDGF/p75 expression.
Artemisinin, an inhibitor of Sp1, or SiRNA knockdown of
SP1 downregulated expression of LEDGF/p75 protein
As a further step toward understanding whether Sp1 is involved
in increased expression of LEDGF/p75, we treated LECs with
various doses of artemisinin (ART). Previous studies established
that ART inhibits regulatory activity of Sp1 to its target gene
expression [33]. LECs cultured with variable concentrations of
ART (0, 50, 150, 300 mM) were processed for Western analysis.
Anti-LEDGF/p75 immunostaining revealed a concentration-
dependent decrease in LEDGF/p75 protein expression in treated
LECs (Fig. 1F), while no change occurred in expression level of b-
actin (internal control), demonstrating that ART specifically and
selectively inhibited Sp1-dependent expression of LEDGF/p75.
ART did not affect the expression level of Sp1 (Fig. 1F, middle
panel), indicating that transcriptional activity of Sp1 was essential
for LEDGF/p75 expression.
To further confirm direct involvement of Sp1 in activating
LEDGF/p75 transcription, we depleted endogenous Sp1 expres-
sion either by transiently (Fig. 1G) or stably (Fig. 1H) transfecting
cells with shRNA specific to Sp1 as described in the Materials and
Methods section. The expression level of endogenous Sp1 was
markedly and specifically reduced by transfection of Sp1 shRNA
in concentration-dependent fashion, but Si control did not show
altered expression level of Sp1. Next we analyzed expression level
of LEDGF/p75 by reprobing the same membrane with antibody
specific to LEDGF/p75. As expected, the expression level of
endogenous LEDGF/p75 was decreased, and the decrease was
directly correlated with expression levels of Sp1. In contrast, Si
control did not alter the level of LEDGF/p75 (Fig. 1G and 1H).
Collectively, the data indicate that Sp1 regulates LEDGF/p75
expression.
Bioinformatic analysis of 59-flanking sequence showed
that human LEDGF/p75 gene is a GC rich TATA-less
promoter containing three putative Sp1 regulatory
elements
In previous reports, we described the structural organization of
LEDGF/p75 protein [34] and cloning of genomic fragments
containing the 59-flanking region of LEDGF/p75 ranging from
25139/+35, and we identified the proximal promoter essential for
LEDGF/p75 promoter activity [20]. Since the patterns of core
promoter may differ in different cells due to variability in
transcription start site (TSS), we determined TSS of LEDGF/p75
gene (S1) [35]. Using RNA isolated from hLECs, we found that
the LEDGF/p75 gene contained three TSSs; one major and two
minor, as shown in Fig. S1. We identified the location of core
promoter of LEDGF/p75 based on major TSS. In the current
work we attempted to delineate the regulatory element(s)
responsible for LEDGF/p75 gene transcription. Sequence analysis
of LEDGF/p75 gene showed that the proximal region (2170/+35)
was relatively enriched with G/C content and, most importantly,
had an apparent absence of CCAAT and TATA boxes (Fig. 2A) as
is common with many GC-rich promoters. In TATA–less
promoter, Sp1 regulatory element appeared to play a pivotal role
in gene transcription [36]. Further analysis of the promoter region
using MatInspector (Genomatix) revealed the presence of three
Sp1-like binding sites within the G/C rich region (Fig. 2A and 2B,
Sp1-1(nCCCGCCCCn), Sp1-2 (nCCCTCCCCn), and Sp1-3
(nGGGGCGGGn). The sites consisted of heterogeneous sequenc-
es that matched all or at least five of the six nucleotides for a
canonical Sp1 binding site [24]. However, consensus sequences for
predicted Sp1-1 and Sp1-2 binding sites were on antisense strand,
and Sp1-3 was on the sense-strand of LEDGF/p75 gene. Sp1 sites
present in either orientation have been shown to be capable of
activating transcription [24,36]. Interestingly, Sp1 sequences in
LEDGF/p75 gene can be classified into two parts, a GC rich region
containing consensus Sp1 sequence (Sp1-3), and a region enriched
with T/TCCCC repeats bearing Sp1-1 and Sp1-2 sites. Further-
more, a comparison of LEDGF/p75 59-flanking region sequences
among mouse, rat and human cells revealed that proximal region
containing Sp1 regulatory elements is highly conserved among
them (Fig. 2B), indicating the importance of Sp1 regulatory
elements in LEDGF/p75 promoter.
To identify and characterize the functionality of Sp1 sites and
their contribution to regulating LEDGF/p75 transcription, we
conducted transfection and transactivation experiments, and
correlated results with the endogenous expression pattern of
LEDGF/p75. We also utilized Sp1-deficient Drosophila cell lines
(SL2).
Transcriptional analysis revealed three functional Sp1
regulatory elements of human LEDGF/p75 promoter
In a previous report [20], using a series of mutation deletion
constructs of LEDGF/p75 promoter linked to TSS (Fig. 2A, +1).
However, regulatory elements involved in LEDGF/p75 transcrip-
tion were not characterized. In the present study, we engineered a
series of deletion mutant constructs linked to CAT (Fig. 2A) to
further define functioning of promoter region containing Sp1 sites
with common 39 end (+35). In the transactivation assay (Fig. 3A),
construct (2170/+35) containing three Sp1 putative sites or
construct (2127/+35) with two showed transcriptional activity,
while in Construct C, containing only one Sp1 site (263/+35),
promoter activity was significantly reduced. However, in Con-
struct D, with no Sp1 site, the CAT activity was insignificant and
was comparable to CAT vector activity alone. Data analysis
demonstrated that the functional cis regulatory elements may
reside in the approximately 144 bp region between 2170 and
228.
Next, we examined the activity of each Sp1 site predicted by
Web-based analysis (MatInspector, Genomatix). Data from
transactivation experiments with different deletion mutant con-
structs of LEDGF/p75 promoter implied that the positive
regulatory element(s) lay in the proximal promoter region
spanning from 2170 to 228 bps (Fig. 3A). This region contained
all three Sp1 sites, suggesting that all may contribute cooperatively
and efficiently to regulate LEDGF/p75 gene transcription. To test
the functionality and contribution of each Sp1 site present in the
region, we made a series of point mutations in core consensus
LEDGF/p75 Regulation by Sp1
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Mut-3 (250/243) site, GC to TT; Sp1-Mut-2 (2109/2102) site,
CC to TA; and Sp1-Mut-1 (2146/2139) site, CC to TT were
mutated. Sp1 is known to play a role in the regulation of GC-rich
genes lacking a TATA box. Transactivation assay with mutant
promoters in LECs revealed that disruption of any of Sp1-Mut-3
and Sp1-Mut-1 resulted in significantly reduced promoter activity
(p,0.001). Surprisingly, mutant construct Sp1-Mut-2 released the
promoter activity dramatically in contrast to the other two Sp1
sites (Fig. 3B), showing this site acted as a repressor. Mutation of
the Sp1-Mut-3 or Mut-1 site showed greater reduction in
promoter activity, and those sites had similar activation potential,
demonstrating that both had acted as transactivator [Fig. 3B, Sp1-
3 (Mut-3) and Sp1-1(Mut-1)].
We also examined combinatorial effects of Sp1 sites. Sp1-Mut-
2+3 with double mutation displayed promoter activity similar to
Sp1-Mut-3 and Sp1-Mut-1, suggesting that the repressive function
of Sp1-Mut-2 site was attenuated significantly in the presence of
Sp1-3 as an activator. Double mutation at Sp1-Mut-1+3, however,
showed further reduction in promoter activity, emphasizing that
the nature of regulatory activity is the same for both sites. The
construct Sp1-Mut-1+2+3, in which all three sites were disrupted,
showed reduction in promoter activity similar to that with mutant
construct (Sp1-Mut-1+3) (Fig. 3B), suggesting that all sites function
in the control of LEDGF/p75 promoter activity under normal
cellular physiological conditions. Similar results were obtained in
other cell lines (mouse lens epithelial cells [mLECs] and Cos7 cells,
data not shown).
Notably, the promoter activity of mutated constructs (Sp1-Mut-
2) did not attenuate WT-promoter activity, but rather released and
enhanced the activity when compared to wild-type (Fig. 3B, Sp1-
WT vs Sp1-Mut-2, p,0.01) or other mutant promoter, and the
increase in activity was dependent on Sp1-Mut-2 site. We think
that each of the three sites of Sp1 in LEDGF/p75 gene promoter
has different transactivation potential, and thus the sites responded
differently. This suggests that Sp1 is a regulator and is also
involved in controlling the magnitude of transcription required for
cellular background. In addition, variation in consensus sequences
in Sp1 sites may change binding affinity that influences the
transactivation potential of Sp1 [32]. We believe that the diverse
sequences from consensus binding sites (sequences) were evolved
during natural selection for cellular benefit. Thus, each of the Sp1
sites contributes to controlling LEDGF/p75 transcription. Two Sp1
responsive element sites, 250 to 243 and 2146 to 2139, are
essential for activation of LEDGF/p75 gene, while an Sp1 site at
position 2109 to 2102 represses the promoter activity. Collec-
tively, the data provide evidence that Sp1 regulatory elements in
LEDGF/p75 promoter are responsible for LEDGF/p75 expres-
sion.
Figure 2. A construct linking the 59 proximal promoter region of the TATA-less LEDGF/p75 promoter to CAT reporter gene showing
putative characteristic features. A, The 59- sequence ranging from nucleotides 2315 to +35 contained three putative Sp1 binding sites as
predicted by MatInspector (Genomatix). The consensus sequences for the predicted Sp1 sites (G/C boxes) are shown in bold and sites are denoted as
Sp1-1, Sp1-2 and Sp1-3. Underlining is used to show the oligonucleotides employed in gel-shift and gel-shift immuno-deletion assays. The
transcription start site is indicated by +1, and letter Mlu I and Nhe I restriction sites used for preparing LEDGF/p75-CAT constructs are shown in italic
and bold. B, Nucleotide sequences alignment of the proximal promoter of mouse, rat and human LEDGF/p75 gene (NCBI, BLAST and alignment tools).
Sequences highlighted in gray are highly conserved among these species, and three evolutionarily conserved Sp1 binding sites are shown in bold
letters.
doi:10.1371/journal.pone.0037012.g002
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of cells directly and selectively interacted with its
regulatory elements in the LEDGF/p75 promoter
To examine whether Sp1 regulatory elements (Fig. 2A, Sp1-1,
Sp1-2 and Sp1-3) in the human LEDGF/p75 promoter directly
bound to Sp1 in nuclear extract of hLECs, double stranded DNA
oligonucleotides containing Sp1 site(s) (as in LEDGF/p75 promot-
er, Fig. 2A) and their mutants were chemically synthesized. These
32p-radiolabelled probes (Fig. 4) were utilized in gel-shift assay. All
oligonucleotides showed sequence-specific binding of Sp1 proteins,
although some sequences differed from the defined canonical Sp1
consensus sequence [37]. A representative gel-shift assay using all
three WT-probes and their mutants is shown in Fig. 4A. All three
DNA probes formed complex (Sp1/DNA) with nuclear extract
(Fig. 4A, lanes; 1, 3 and 5). In contrast, their corresponding mutant
probes did not form Sp1/DNA complex with the nuclear extract
(Fig. 4A: lanes 2, 4 and 6) (Fig. 4A: Mutant probe; underlined nt,
G to T/A and C to T/A). A band (NS) appeared in all lanes with
approximately the same intensity, signifying a nonspecific entity.
Next, we examined whether the increased abundance of Sp1
protein in nuclear extract would show increased binding to oligo-
containing Sp1 sites. We over expressed hLECs with Sp1 by
transfecting them with pCMV-Sp1 eukaryotic expression con-
structs. Nuclear extract derived from these cells interacted with
probe (WT-Probe1) and gave rise to Sp1/DNA complex (Cm1) of
higher intensity than in the control, which did not overexpress Sp1
(Fig. 4B; lane 1 vs 3). No Sp1/DNA complex was detected with a
mutant probe containing disrupted Sp1 consensus (Fig. 4B, lanes 2
and 4), further suggesting that Sp1 selectively bound to its sites. We
also verified the integrity of DNA and protein (nuclear extract)
interaction by using standard control probe containing Sp1 sites
(sc-2502 or its mutant sc-2503) and Sp1 in nuclear extract. Fig. 4B,
lanes 7 and 8 show the binding of Sp1 in nuclear extract to the
probe, suggesting consistent interaction among probes (Sp1-1,
Sp1-2 or Sp1-3) bearing putative Sp1 sites. To examine whether
binding of Sp1 was specific to probes, we conducted antibody
depletion assay using antibody specific to Sp1. Nuclear extract
absorbed with anti-Sp1 antibody showed reduced or no binding to
Figure 3. Transcriptional activity of LEDGF/p75 promoter and identification of functioning potential of Sp1 sites within human
LEDGF/p75 promoter. A, Left half, diagrams showing the 59-deletion constructs of LEDGF/p75 promoter linked to CAT reporter gene used for
transient transfections. Right half, CAT activity of the LEDGF/p75 promoter deletion constructs and empty CAT vector in hLECs. 59-deletion mutant
constructs and pGFP were cotransfected into hLECs. 48 h later, protein was extracted and CAT activity was measured. CAT activity (right) was
normalized to GFP readings (O.D.). The data represent the mean 6 S.D. from three independent experiments. B, Point mutation analysis showing Sp1
site-dependent transcriptional activity of the LEDGF/p75 gene promoter in hLECs. Left half, schematic representation of Sp1-site-directed mutants of
LEDGF/p75 promoter linked to CAT. Right half, CAT activity of the wild-type (WT) and its mutant constructs (Mut-3, Mut-2, Mut-1 and Mut- 1+2+3) and
empty CAT vector in hLECs. All data are presented as the mean 6 S.D. derived from three independent experiments (*p,0.01, **p,0.001).
doi:10.1371/journal.pone.0037012.g003
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nuclear extract absorbed with normal rabbit IgG (Fig. 4B, lane 5),
demonstrating that Sp1 bound specifically to probe. Since Sp1 and
Sp3 bound the same consensus sequence elements [24], to ensure
that Sp1 bound specifically and exclusively to probe, we
performed gel-shift assay with antibody-depletion experiments by
incubating antibody specific to Sp3 with nuclear extract. We found
that Sp3 antibody did not influence complex mobility and integrity
on gel, demonstrating that Sp3 did not occupy the Sp1-binding
elements (Fig. 4B, lanes 9 and 10). Similar results were obtained in
experiments with other two probes containing Sp1 sites or its
mutant site (data not shown).
In vitro data suggested that Sp1 exclusively bound to its putative
regulatory elements within the LEDGF/p75 promoter. However,
to determine if the regulation of LEDGF/p75 transcription by Sp1
occurred via a direct mechanism in vivo, we employed chromatin
immunoprecipitation assay (ChIP) to measure the occupancy of
Sp1. We utilized identified Sp1 response element region in the
LEDGF/p75 promoter (Fig. 5A) and carried out PCR on
chromatin DNA fragment specifically immunocomplexed to
Sp1. After formaldehyde crosslinking and sonication to shear the
chromatin, chromatin fragments were immunoprecipitated from
cultured hLECs with the antibodies anti-Sp1 and control rabbit
IgG. DNA from the immunoprecipitated complex was then
recovered. From this DNA, a fragment of the LEDGF/p75
promoter-containing Sp1 sites was amplified by PCR using a set of
predesigned primers for the region (Fig. 5B). A pair of sense and
antisense primers was also designed, along with a negative control
to amplify a region of genomic DNA beyond 2 kb from Sp1
binding sites. As shown in Fig. 5B, Sp1 specifically bound to the
LEDGF/p75 promoter region containing the Sp1 sites (all three
sites: 2146/2139, 2109/2102, 250/243). No amplicons were
examined with either primer for DNA beyond Sp1 sites or control
IgG (Fig. 5B). These data demonstrate that Sp1 protein bound to
the LEDGF/p75 promoter, and protein DNA complex was
immunoprecipitated by an anti-Sp1 antibody but not by irrelevant
control IgG antibodies (Fig. 5 B, aIgG panels), pointing to the
specificity of immunocomplex produced selectively by anti-Sp1
antibody. This assay did not reflect that all Sp1 sites are involved
selectively or specifically, but gel-shift assay coupled with
transactivation assay clearly indicated that all three Sp1 sites
bound selectively and functionally to Sp1. The functional
significance of this binding was further examined in transactivation
assays using the Sp1 inhibitor artemisinin and/or cells overex-
pressing Sp1.
Artemisinin and Sp1 transfection assays revealed that
LEDGF/p75 transactivation was largely derived from
direct functional binding of Sp1 to LEDGF/p75 promoter
in vivo
Because ART inhibits gene transcription by attenuating/
modifying Sp1 activity [33] and Sp1 selectively binds Sp1-response
elements in the LEDGF/p75 promoter (Figs. 4 and 5), we
hypothesized that ART may abolish LEDGF/p75 transcription,
and thereby provide proof of the concept that Sp1 physically and
Figure 4. Nuclear extract from LECs bound to Sp1 sites present in human LEDGF/p75 promoter. A, Representative gel-shift mobility assays
showing Sp1 binding to radiolabeled oligonucleotide probes containing consensus Sp1 sites as indicated. Nuclear extracts isolated from hLECs were
incubated with
32p-labeled probes containing Sp1 binding sites (WT-probes) or their corresponding mutants (Mut probes). Nuclear extracts bound to
oligos containing Sp1 sites and yielded to complex, Sp1/DNA (Cm1) (A, lanes 1, 3 and 5). No complex occurred with mutant probes (A, lanes 2, 4, and
6). The oligonucleotide probes of both wild-type and mutated sequence used in assay are shown adjacent to image. B, Gel-shift assay showing the
binding of Sp1 in nuclear extract of Sp1 overexpressed with hLECs to
32p-labeled probes with its site. Nuclear extract isolated from cells transfected
with plasmid encoding Sp1 or its corresponding vector was incubated with WT-probe1 or standard control probe (sc-2502; Santa Cruz Biotech). The
DNA-protein complex was resolved on a 5% acrylamide gel. A discrete Sp1 expression-dependent DNA-protein complex was observed (B; lanes 1 vs
3) in comparison to vector transfected cells (lane 1), while the mutated probe failed to generate the complex (B, lanes 2 and 4). B, Right (lanes 5 and 6),
depletion of endogenous Sp1 with its specific antibody. Nuclear extracts were incubated with either anti-Sp1 antibody (lane 6) or normal rabbit IgG
(lane 5), and recovered nuclear extracts were incubated with the same probes (lanes 5 and 6). Lanes 7 and 8, standard control containing
NSp1 site (sc-
2502, Santa Cruz Biotech) or its
@mutant (sc-2503) processed for gel-shift assay using the same nuclear extracts. Extreme right, Depletion assay using
anti-Sp3 antibody with nuclear extract showing no change in Sp1/DNA complex (lane 10) and the complex was indistinguishable from Lane 9. Images
are representatives from three independent consistent observations.
doi:10.1371/journal.pone.0037012.g004
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transfected LECs with LEDGF/p75 gene promoter construct
containing Sp1 response sites (2170/+35) fused to CAT reporter
gene as described in the Materials and Methods section and
reported earlier [20]. Cells were subjected to various concentra-
tions of ART treatment (0, 50, 150, 300 mM) or to vehicle control.
Analysis of CAT activity showed that ART strongly suppressed
promoter activity of LEDGF/p75 even at the minimum concen-
tration, 50 mM (Fig. 6A, black bar). This result is consistent with
an earlier published report that ART blocks Sp1 transcriptional
activity [33]. We concluded that loss of interaction of Sp1 with its
cis-elements in the promoter may account for the loss of LEDGF/
p75 transcription as well as for downregulation of LEDGF/p75
protein (Fig. 1E).
We next examined the transcriptional effects of cellular
abundance of Sp1 on the magnitude of LEDGF/p75 transcription.
Cells were cotransfected with LEDGF/p75 promoter (2170/+35)
containing Sp1 sites along with different concentrations of pCMV-
Sp1. Cells cotransfected with Sp1 constructs caused robust
induction of CAT activity, which increased with increased
abundance of Sp1 (Fig. 6B upper panel, Western blot; lower
panel, black bars). Next, we tested Sp1 activation of the same
promoter in Cos7 cells (Fig. 6C upper panel, Western blot image;
lower panel, black bars). Comparison of Fig. 6B and 6C reveals
that the effect of Sp1 on LEDGF/p75 promoter transcription was
similar in both cell types, while cells not overexpressed with Sp1
showed basal levels of CAT activity (Fig. 6 B and C, open bar).
These results demonstrated that Sp1 sites present in LEDGF/p75
promoter were the functional Sp1 binding sites, and were
responsive to cellular abundance of Sp1.
Transcriptional analysis of LEDGF/p75 gene promoter in
Drosophila cell lines showed that Sp1 functionally
determined LEDGF/p75 transcription
Sp3 is a ubiquitous transcriptional protein that is highly
homologous to Sp1 [24] and competes for the same DNA
elements. To exclude the possibility of Sp3 involvement, we
utilized Sp1-deficient Drosophila cell line (SL2), even though gel-
mobility depletion assay showed no Sp3 involvement on identified
Sp1 sites of LEDGF/p75 promoter (Fig. 4B). To address the
selective regulation of LEDGF/p75 promoter by Sp1, we
cotransfected SL2 cells with LEDGF/p75 promoter linked to
CAT reporter construct or its mutant in the presence or absence of
expression plasmids encoding Sp1 (pPac-Sp1) or pPac-vector.
Thus the transactivation of the LEDGF/p75 promoter-containing
Sp1 sites was largely dependent on the ectopically introduced
transcriptional protein, Sp1. Analysis of data revealed that
Figure 5. ChIP analysis of genomic DNA from hLECs revealed Sp1 binding to LEDGF/p75 promoter in vivo. A, Schematic illustration of 59-
proximal promoter region of LEDGF/p75 containing Sp1 binding sites. Genomic DNA was cross-linked to immobilize bound proteins in vivo, was
sheared and immunoprecipitated with anti-Sp1 or unrelated antibody rabbit IgG, and was amplified by PCR with primer specific to the region. The
quantity of each input DNA was initially measured equalized by O.D. A representative gel stained with ethidium bromide is shown. As a control
measure, amplification of the 22499/22277 region (*) devoid of Sp1 elements of LEDGF/p75 promoter following immunoprecipitation was
performed. B, Photographic image of the amplified DNA band visualized with ethidium bromide staining. M, molecular weight marker. Lower half,
primers used for amplification of specific region containing Sp1 sites (
**Sp1-1,
***Sp1-2,
****Sp1-3) and not related to Sp1 binding sites (
*).
doi:10.1371/journal.pone.0037012.g005
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stimulated (,12 fold) in pPac-Sp1 transfected cells (Fig. 7B, gray
bar vs black bar), whereas residual activity remained with mutant
construct (mutated at all sites, Sp1-Mut-1+2+3). This nonspecific
activity may be related to certain unidentified factors in SL2 cells.
However, CAT-basic vector was not activated by Sp1.
Additionally, we prepared cell extract from Sp1 transfected Sp1-
deficient SL2 cells and conducted DNA-Sp1 binding assay. Cell
Figure 6. Sp1 expression levels had an impact on modulation of LEDGF/p75 promoter activity. A, Interrupting Sp1 activity by artemisinin
interrupted LEDGF/p75 promoter activity in a concentration-dependent manner. Upper panel, a diagram of the LEDGF/p75 promoter representing
three Sp1-binding sites (2170/+35) used for CAT activity. A selective Sp1 inhibitor [33], artemisinin, reduced the activity of LEDGF/p75 promoter in
LECs in dose-dependent fashion. Artemisinin or its diluents (control) were added to culture medium of LEDGF/p75 promoter constructs or empty
vector transfected cells monolayer. Cells were disrupted and CAT activities were measured as described in the Materials and Methods section. Data
are the mean of three experiments, and error bars indicate standard deviation (**p,0.001). B and C, Influence of Sp1 overexpression on
transcriptional activity of LEDGF/p75 promoter. Plasmid encoding pCAT-LEDGF/p75 (2170/+35) or pCAT-V was cotransfected into hLECs (B) and Cos7
cells (C) with indicated amounts of pCMV-Sp1. Following CAT assay, CAT values were analyzed and represented as histograms, with Sp1 (black bar) or
without Sp1 (open bar) overexpression. Empty CAT vector shows insignificant CAT activity (gray bar). Transfections were carried out as described in
Materials and Methods and level of Sp1 protein was evaluated using Western analysis (B and C, Upper panel). The data are representative of at least
three independent experiments. Each value represents the mean 6 S.D. (**p,0.001).
doi:10.1371/journal.pone.0037012.g006
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after verification of Sp1 expression (Fig. 7A). Fig. 7C shows that
32p-radiolabeled probe containing Sp1 sites interacted with cell
extract and formed complex (Cm 1) (Fig. 7C, lane 2), while nuclear
extract from Sp1-deficient SL2 cells or mutant probe did not
(Fig. 7C, lanes 1 and 3), demonstrating that Sp1 regulatory
elements in the LEDGF/p75 promoter are sites for Sp1 binding.
Similar results were obtained with the other two Sp1 sites (Sp1-2
and Sp1-3, data not shown). As standard control, oligonucleotides
containing the Sp1 sites (59-ATTCGATCGUGGUGCGGGGC-
GAGC-39; catalog number sc-2502; Santa Cruz Biotech) and its
mutant ‘GG’t o‘ TT’ (sc-2503) were used to verify the results. Gel-
shift assay demonstrated that nuclear extract isolated from SL2
cells ectopically expressing Sp1 was able to strongly bind to wild-
type Sp1 probe, forming Cm1 complex (Fig. 7C, lane 4); nuclear
extract from Sp1-deficient SL2 cells or mutant probe did not,
indicating the integrity of the experiments. A band (NS) appeared
signifying nonspecific entity or changes in nuclear proteins in SL2
Figure 7. Sp1 expression in Sp1-deficient SL2 cells showed that Sp1 transactivated LEDGF/p75 promoter by direct binding to its
sites. A, SL2 cells, a Drosophila cell line, were transfected with indicated amounts of pPac-Sp1 (lanes 2 and 3) or pPac-V (lane 1). The expression level
of Sp1 protein was examined by Western blot. Relative band density is shown below (A, gray bar vs black bar). B, Increasing Sp1 expression selectively
increased LEDGF/p75 promoter activity in SL2 cells. SL2 cells were cotransfected with pPac-Sp1 or pPac-vector (pPac-V) and pCAT-LEDGF/p75 wild-
type (pCAT-LED) or its mutant (pCAT-LED-Mut) reporter plasmid or pCAT vector (pCAT-V). Cells were processed to assay CAT activity as described in
Materials and Methods. Results were expressed relative to activity of the LEDGF/p75 reporter activity in the presence of pPac-V or pPac-Sp1 and are
presented as histograms: pPac-Sp1 with WT promoter (gray bar), and pPac-Sp1 with mutant promoter activity (open bar). The results are mean 6 S.D.
of three independent experiments (** p,0.001). C, Sp1 directly and exclusively bound to its sites in LEDGF/p75 promoter. Nuclear extract was isolated
and processed and then incubated with radio-labeled DNA probe containing Sp1 site (Probe 1 or standard control probe,
NSp1). Nuclear extract from
pPac-Sp1 overexpressed cells bound strongly to probe containing wild-type Sp1 consensus sequence (lane 2), but nuclear extract from pPac-vector
transfected cells showed no binding with either wild-type or mutant probe (lanes 1 and 3). Right panel, Nuclear extracts of pPac-Sp1 transfected cells
incubated with standard control probe containing Sp1 site (sc-2502, lane 4) or its mutant (sc-2503, lane 5) and nuclear extract from pPac vector
transfected cells incubated with standard probe (lane 6).
doi:10.1371/journal.pone.0037012.g007
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DNA-binding property. Taken together, data reveal that tran-
scriptional protein Sp1 transactivated human LEDGF/p75 pro-
moter by directly binding to its sites.
Sp1 Sumoylation negatively regulated LEDGF/p75 gene
transcription
Several recent studies have shown that Sumoylation of Sp1
represses gene transcription by regulating Sp1 expression [29,38].
To study how this modification of Sp1 affects LEDGF/p75
transcription, we cotransfected hLECs with LEDGF/p75 promot-
er-CAT construct (2170/+35) and plasmid encoding pCMV-Sp1
and/or Sumo1 (pEFGP-Sumo1) in increasing amounts (2, 4, and
8 mg). Fig. 8 illustrates a decrease in LEDGF/p75 promoter activity
with increasing concentrations of Sumo1 (Fig. 8 A, gray bar).
Results indicate that the CAT effect driven by LEDGF/p75
promoter upon the expression of Sp1 was repressed by Sumo1.
To determine if Sumoylation/desumoylation affects the DNA-
binding activity of Sp1 in vivo, we carried out a ChIP assay.
Following transfection/cotransfection of hLECs with required
encoding plasmids (pCMV-Sp1 and/or pEGFP-Sumo1 and/or
pFLAG-Senp1 or their controls), we prepared chromatin samples
as described in the Materials and Methods section. The Sp1
antibody, Sp3 antibody or control rabbit IgG immunoprecipitated
complex were processed and analyzed by PCR using primers
specific to promoter region. Fig. 8B shows that Sumo1 overex-
pression significantly reduced Sp1 binding with the endogenous
LEDGF/p75 gene (lanes 1 and 5), and this binding was increased
in cells overexpressing Sp1 (lane 2) or Senp1 (lane 3). In contrast,
the region not related to Sp1 did not provide detectable interaction
between Sp1 and LEDGF/p75 promoter. In another experiment,
following immunoprecipitation with Sp1 or Sp3 antibody or IgG,
the chromatin-bound proteins were eluted with high salt buffer,
and were electrophoretically resolved and analyzed by immuno-
blot using Sp1 or Sp3 specific antibody. Analysis revealed that
Figure 8. Sumoylation of Sp1 repressed LEDGF/p75 gene transcription by decreasing the abundance of Sp1 to DNA. A, Repression of
LEDGF/p75 transcription by Sp1 Sumoylation. Cells were transfected or cotransfected with pCAT-LEDGF/p75 (pCAT-LED) or pCAT vector (pCAT-V) and/
or with increasing amounts of a plasmid encoding Sumo1 (pEGFP-Sumo1) as indicated. Cells were disrupted at predefined times and processed for
CAT assay. Data indicate CAT activity in cells overexpressing different amounts of Sumo1 (A, gray bars) and without Sumo1 (black bars). Experiments
were performed three times, and data are presented as mean 6 S.D. B, ChIP assay coupled with desumoylation and DNA-protein complex
dissociation experiments showed that the effect of Sumo1 on the abundance of Sp1 was concentration-dependent. hLECs were transfected with
either pCMV-Sp1 alone or cotransfected with pEGFP-Sumo1 or pFLAG-Senp1. ChIP assay was performed in duplicates from each sample with anti-Sp1
or anti-Sp3 antibody or control IgG. Following processing, one set of precipitated samples was submitted for PCR analysis of Sp1 responsive region of
LEDGF/p75 promoter (B) as described in Materials and Methods. In another set of experiments, DNA bound proteins were eluted with high salt
solution, and Western analysis was performed on elutes to measure Sp1 prevalence by anti-Sp1-antibody (C: lane 1, pCMV-Sp1; lane 2, pEGFP-Sumo1;
lane 3, pFLAG-Senp1; lane 4, pCMV-Sp1 plus pEGFP-Sumo1; lane 5, pCMV-Sp1 plus pFLAG-Senp1; p-vector). Images shown in the panel (B) are of
representatives of Sp1-3 (site 3) region. Similar results were obtained with Sp1-1 (site 1) and Sp1-2 (site 2) in the LEDGF/p75 promoter when ChIP-PCR
analysis was done (data not shown). Following stripping of Sp1 immunoblotted membrane, the same membrane was reprobed with Sp3 specific
antibody, and no bands were observed (D).
doi:10.1371/journal.pone.0037012.g008
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making it less available to LEDGF/p75 gene promoter (Fig. 8C,
lanes 2 and 4). In contrast, an abundance of Sp1 protein was
detected in cells overexpressed with Sp1 or Senp1. These data
were consistent with previous studies reporting that Sumoylation
of Sp1 reduces the abundance of cellular Sp1, leading to negative
regulation of Sp1 target gene transcription [29]. No band was
obtained or detected when the membrane was reprobed with Sp3
antibody (Fig. 8D). Similar results were obtained with two other
Sp1-2 and Sp1-1 sites in LEDGF/p75 promoter (data not shown).
RNA-interference and Sp1 overexpression experiments
revealed that LEDGF/p75 was essential for hLEC survival
in UVB-induced stress
LECs, the outermost cellular layer of the human lens, are
exposed maximally to UV irradiation, suggesting that these cells
are under continuous oxidative stress [39]. Studies have shown
that LEDGF/p75’s physiological expression level is vitally
important, as it provides cytoprotection [5,19,40]. To study
whether reduced expression of LEDGF/p75 influences cellular
viability, we employed siRNA strategy to knock down the
LEDGF/p75 expression in hLECs. The hLECs were transfected
with the vector-based siRNA carrying selection marker [41].
Stably transfected cells were screened for LEDGF/p75 expression
by Western analysis (Fig. 9A, left panel: images; right panel:
histogram, densitometry of the band). The cells with reduced levels
of LEDGF/p75 when exposed to UVB were less viable as revealed
by MTS assay (Fig. 9B). Interestingly, overexpression of Sp1 to
these cells failed to offer significant protection (Fig. 9C), while
normal cells overexpressing LEDGF/p75 or Sp1 showed signif-
icant resistance against UV radiation-induced stresses compared to
control, pEGFP empty vector transfected cells, indicating that
cellular protection against UVB stress was caused by overexpres-
sion of LEDGF/p75 or Sp1-dependent increased expression. The
results revealed that Sp1, a regulator of LEDGF/p75 gene
transcription, can be manipulated, potentially for development
of Sp1-dependent LEDGF/p75 expression-based therapeutics.
Discussion
LEDGF/p75 is a nuclear protein expressed in many cell types
[2,6,7]. It enhances cellular survival by increasing the expression
of stress-associated genes and small heat shock proteins (hsps)
through interacting stress response (STRE) and heat shock protein
gene response elements (HSE) in these genes [2,5,6,19], acting as a
transcription factor. Recent evidence revealed that DNA binding
activity of LEDGF/p75 is not limited to STRE or HSE in the
stress-associated genes, but LEDGF/p75 also binds to supercoiled
DNA [22] and active chromatin markers as well as RNA
polymerase II, and is associated with transcriptional activity of
the transcriptional unit [21,22]. LEDGF/p75 gene inactivation has
been shown to result in perinatal mortality and complex
phenotype abnormalities [1]. LEDGF/p75’s diverse and dynamic
patterns of expression which account for its diverse mode of
biological action are now well recognized. Less well understood
are the processes by which expression levels of LEDGF/p75 are
regulated. In the present study, we observed that LEDGF/p75
expression was modulated in hLECs isolated from eye lenses of
different ages, and the expression pattern of LEDGF/p75 was well
correlated with Sp1 expression levels (Fig. 1). Our studies of Sp1
overexpression and inhibition of Sp1 activity by artemisinin and
Sp1 shRNA revealed that the modulation in expression of
LEDGF/p75 protein or mRNA depended upon abundance of
Sp1 expression (Fig. 1). These results argue that Sp1 can be a
regulator of LEDGF/p75 transcription. Sp1, a C2H2 zinc finger-
containing factor, is a constitutively expressed protein that
naturally engages in transregulating various TATA-less or TATA
box-containing gene promoters. The promoter regions of these
human genes are usually GC-rich, and, by definition, these genes
are expressed ubiquitously [42,43].
As expected, in silico analysis has identified three Sp1 sites within
the GC-rich proximal promoter region of LEDGF/p75 gene
(2170/+1), and has revealed that LEDGF/p75 is devoid of TATA-
and CCAAT-boxes (Fig. 2), consistent with its constitutive
expression in LECs and many other cell types [6,20,44]. A
comprehensive and comparative analysis of sequences within 59-
flanking region of LEDGF/p75 gene by DNA (ClustalW, a Web-
based program for DNA sequence) revealed that the region with
GC-Boxes and without TATA and CCAAT boxes is well
conserved in mammals, further emphasizing the importance of
Sp1 sites within the region (Fig. 2B). Based on our initial study
(Fig. 1), coupled with bioinformatics analyses showing the presence
of three putative Sp1 regulatory elements (Sp1-1, Sp1-2, Sp1-3)
and Sp1 abundance-dependent increased expression of LEDGF/
p75 mRNA (Fig. 1), we speculated that Sp1 sites may play a role in
regulating LEDGF/p75. Deletion analysis showed that the
promoter construct lacking Sp1 regulatory element (228/+35)
was not responsive and CAT activity was indistinguishable from
CAT vector activity (Fig. 3A), indicating that LEDGF/p75
transcription was dependent upon Sp1-DNA binding. More
definitive evidence was produced by site-specific mutagenesis,
which demonstrated that Sp1-1 (2146/2139) and Sp1-3 (250/
243) have greater transactivation potential and enhance LEDGF/
p75 promoter activity. Surprisingly, however, Sp1-2 (2109/2102)
acts as a repressor regulatory element, as disruption of its site
enhanced promoter activity (Fig. 3B). Among all the Sp1 sites in
LEDGF/p75 promoter, Sp1-1 regulatory element showed the
highest transactivation potential. However, overall, the promoter
activity of LEDGF/p75 was increased, emphasizing that all three
Sp1 regulatory elements are involved in controlling promoter
activity. We believe that all three sites with their different
transactivation potential are evolutionarily conserved for the
purpose of controlling expression levels of LEDGF/p75. Addi-
tionally, we propose that the repressive regulatory element Sp1-2 is
highly important for fine tuning of LEDGF/p75 transcription. If
this process goes awry, the result may be aberrant expression of
LEDGF/p75.
Recently genome-wide analysis have indicated that the majority
of genes contain multiple functional start sites, which are present
in the core promoter region [35]. Furthermore, aberrant TSS
usage has been associated with aberrant expression of transcripts
and has been found to be linked to cellular abnormalities-such as
cancer. In the current study, we found that LEDGF/p75 promoter
consists of three TSSs: one major and two minor start sites (Fig.
S1). We utilized major TSS sites to prepare deletion constructs of
LEDGF/p75 promoter. However, another laboratory reported
recently that LEDGF/p75 had different TSSs [45] from those that
we found in lens epithelial cells (S1). Careful analysis revealed that
TSS of LEDGF/p75 reported by previously published work by
Desfarges et al [45] is located +208 nt downstream of TSS defined
in our work (Fig. 2). We believe that the discrepancy may be due to
the use of different cell types or cell background. Recently several
genes have been found to have multiple transcription start points.
A correlation between TATA-less promoters and multiple TSS
usage has been generally accepted [46]. This feature of LEDGF/
p75 promoter demonstrates that its regulation is indeed complex.
TSS may provide an extended transcriptional platform that can
accommodate diverse transcriptional cofactors with different
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cofactors may utilize distinct transcription initiation sites, and
may be differentially regulated [47], in turn controlling the
expression of genes such as LEDGF/p75.
Furthermore, more than 50% of human genes contain putative
alternative promoters, and these genes are regulated by multiple
promoters with different TSSs [48,49]. Most of these genes belong
to several cancer-associated genes such as MYC and BRCA1
[50,51]. Several recent reports have indicated that LEDGF/p75 is
associated with cancer, [3,10,40,52], and its aberrant expression
leads to cancer progression [52]. Based on our current work and
that of [45], we can surmise that LEDGF/p75 contains alternative
promoter (at least dual promoter) that influences the transcrip-
tional level of LEDGF/p75 in the cell background. Interestingly,
the promoter identified in our work has critically important
features that are well conserved among mouse, rat and human
cells: (i) it has a stretch of GC dinucleotide, (ii) it contains Sp1
responsive elements, and (iii) it does not contain TATA and
CATAA boxes. Overall the structural characteristics of promoter
strongly argue that it is evolutionarily conserved, and thus is
functionally important and distinctly regulated. Comparison of the
study presented here with recent reports [45] on regulation of
LEDGF/p75 gene transcription indicates that the LEDGF/p75
gene may have alternative promoter that may function differently.
However, further work is required to understand how and when
LEDGF/p75 promoter activity is altered in reference to cell
background.
Our new TSS with alternative promoter is different from gene
promoter recently reported [45], and redefining proximal
promoter (Fig. 2). As defined in our current work, 2170 bp of
proximal promoter contained functional Sp1 responsive elements
which greatly differ from those reported by Desfarges et al. [45]. In
eukaryotes, alternative promoters have been documented for
many tissue-specific and developmentally regulated genes in
response to internal and external stimuli [53]. In most cases,
transcripts originated from an active alternative promoter differ
only in their 59-untranslated region (UTR), but share the same
coding sequence. Our new TSS adds as much as 208 bp to the 59-
UTR of LEDGF/p75 reported by Desfarges et al. [45]. This
additional region of contains Sp1 sites responsible for LEDGF/p75
transcription as reported by Desfarges et al. [45]. Moreover, an
increasing number of studies identify the existence of alternate
promoters for human genes and their differential usage as one
important source of regulatory diversity [54]. We believe that the
presence of multiple TSS or alternative promoter can add
flexibility to the ways in which LEDGF/p75 gene expression is
regulated, can potentially affect translational efficiency, and can
provide tissue, developmental, or signal specificity [53].
Figure 9. Small interfering RNA (siRNA) silencing of LEDGF/p75 revealed that hLECs were vulnerable to UVB-induced injury. A,
hLECs were transfected with either mock, negative control siRNA or LEDGF/p75 siRNA. Following transfection, cell extracts were prepared and
expression was examined by Western analysis using Anti-LEDGF/p75 antibody (A). Relative density in pixels is shown on the right. B, Control siRNA
(siControl) or LEDGF/p75 siRNA (siLEDGF/p75) transfected cells were seeded in 12-well plates and submitted to UVB exposure as described in
Materials and Methods. A survival assay-MTS assay was conducted, and data shown are mean 6 S.D. values of three independent experiments. **
p,0.001 compared with control siRNA. C, Sp1 overexpression in cells with siRNA LEDGF/p75 conferred resistance against UVB stress. LEDGF/p75
siRNA transfected hLECs were transiently re-transfected with pCMV-Sp1 and then exposed to UVB stress. MTS assay was performed to evaluate
vulnerability. *p ,0.01 compared with respective controls. D, Sp1 or LEDGF/p75 overexpression in hLECs provided cytoprotection against stress
induced by UVB. Cells were cultured and exposed to different doses of UV stress as indicated. Cell viability was analyzed using MTS assay as described
in Materials and Methods. **p ,0.001 compared with respective controls. Data represent mean 6 S.D. from three independent experiments.
doi:10.1371/journal.pone.0037012.g009
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ally tightly controlled by Sp1, and the regulatory elements of Sp1
that diverge from core consensus sequences contribute specifically
to fine tuning the expression of LEDGF/p75. Analysis of LEDGF/
p75 promoter revealed that it contains nGGGCGGn or nCCA/
GCCCn binding sites. Sp1 is known to recognize both elements
with similar affinities [24]. DNA-protein binding assay using
nuclear extracts from LECs demonstrated that Sp1 directly and
specifically bound to Sp1 sites of LEDGF/p75 promoter, and
intensity of Sp1/DNA complex varied according to configuration
of Sp1 regulatory element(s) (Fig. 4). This illustrates that binding
affinity or intensity did influence activation potential of Sp1
elements, at least in regulating LEDGF/p75 promoter. Based on
the contribution of each Sp1 site in regulating LEDGF/p75
transcription (Fig. 3B), we believe that each Sp1 site within
LEDGF/p75 promoter recruits different cofactors in context with
cell background. Within the Sp family, Sp1 and Sp3 are
ubiquitously expressed, and both can bind to the same cognate
DNA-element [24,36]. However, our in vitro DNA binding and
ChIP assays excluded the possibility of Sp3 binding to either of the
other Sp1 sites (Figs. 4 and 8). Our ChIP assay was not be able to
dissect out Sp1 binding to each Sp1 site, since DNA fragments
obtained in assay were limited to only 200 to 300 bps. However,
we were able to define activity of all three sites of Sp1 using gel-
shift and transactivation assays (Figs. 3, 4, 7). Furthermore, Sp1
has been shown to activate or repress target gene transcription,
depending on the complex with which it interacts [24]. It is
tempting to indicate that an analysis of each Sp1 binding site
revealed that they are different from one another (but diverge from
core binding sequences) and act differently in regulating LEDGF/
p75 transcription. We believe that the different activation potential
of each site is due to recruitment of different factors or cofactors at
the site (Figs. 2, 3, 4 and 5) [55]. However, data from Sp1-deficient
SL2 cells that ectopically express Sp1, coupled with artemisinin
(Fig. 7), indicates that Sp1 is indeed a regulator of LEDGF/p75
transcription (Fig. 6A and B).
Furthermore, both the DNA binding and transactivation
potential of Sp1 may be altered by its posttranslational modifica-
tions exemplified by phosphorylation, Sumoylation, glycosylation
and acetylation [29,38]. Our work showed that LEDGF/p75
transcription is further controlled by Sp1 Sumoylation. Cellular or
environmental stress may modify cellular signaling by mediating
posttranslational modifications of proteins. Sumoylation of tran-
scriptional protein has been shown to modulate transcriptional
activity and affect gene expression and biological functions. In
cotransfection and transactivation experiments, we found that
Sumo1 reduced the transcriptional activity of Sp1 (Fig. 8A). This
finding was supported by ChIP assay (DNA-Sp1 binding assay)
using Sumo1 and Sumo hydrolase, Senp1, in which the DNA
activity of Sp1 was increased significantly in cells transfected with
Senp1. Additionally, in chromatin immunoprecipitation assay with
anti-Sp1 antibody, we found that the reduced activity of LEDGF/
p75 transcription was caused by reduced interaction of Sp1 with
LEDGF/p75 promoter in cells overexpressing Sumo1 (Fig. 8B and
C). These results are consistent with the known effect of Sp1
Sumoylation on transcriptional activity of other genes [29,38].
To further study the functioning of LEDGF/p75 and its
potential correlation with lens epithelial cell biology, we assessed
the effect of LEDGF/p75 or Sp1 expression on survival of LECs
facing stresses. By using LEDGF/p75 specific siRNA, we found
that cells expressing reduced LEDGF/p75 level were more
vulnerable to UVB-induced oxidative stress. Interestingly, stable
transfection (siRNA-LEDGF/p75) of cells overexpressing pCMV-
Sp1 also did not alter cell viability, while LECs overexpressed with
either LEDGF/p75 or Sp1 showed significant resistance against
UVB stress. These findings demonstrate that LEDGF/p75 plays a
major role in protecting LECs from oxidative stress-induced
cellular damage by UVB radiation (Fig. 9).
In summary, we have revealed, for the first time, that Sp1
specifically and differentially regulates human LEDGF/p75 tran-
scription, via directly binding its three cis-regulatory elements
located in LEDGF/p75 promoter. LEDGF/p75 transcription is
additionally controlled by regulatory activity of Sp1. The present
characterization of LEDGF/p75 gene and its interactions with Sp1
and the effect of Sp1 Sumoylation upon LEDGF/p75 transcription
is an initial step toward understanding the molecular mechanism
governing the regulation of LEDGF/p75. Further detailed studies
will be needed to delineate the mechanism involved in the
expression of this physiologically important gene during different
physiological conditions. Finally, the work presented here provides
direct evidence that regulation of LEDGF/p75 is dependent upon
Sp1 activity. Our data suggest that optimizing the expression level




Human lens epithelial cells (hLECs) (a gift of Dr. V. N. Reddy,
Eye Research Institute, Oakland University, Rochester, MI) [56]
and Cos7 cells (ATCC; CRL-1651) [57] were maintained
routinely in our laboratory following the method described
elsewhere [41]. Briefly, cells were cultured in a 75-mm tissue
culture flask in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 15% heat-inactivated fetal bovine serum (FBS),
100 mg/ml streptomycin, and 100 mg/ml penicillin in a 5% CO2
environment at 37uC following standard methods. Cells were
harvested and cultured in 96, 24, 48 or 6 well plates and 100 mm
petri dishes according to the requirements of the experiment.
Isolation of LECs from human subjects
Eye lenses were isolated from human subjects of variable ages
ranging between 16 to 75 years, obtained from the Lions Eye
Bank, Nebraska Medical Center. The lenses were divided into
three age groups: group 1, 16 to 26 years (n=4); group 2, 34 to 42
years (n=3) and group 3, 52 to 75 years (n=7). LECs from these
subjects were generated as described earlier with some modifica-
tion [58]. Briefly, clear lenses were washed with DMEM
containing penicillin-streptomycin (100 mg/ml) and amphotericin
B (25 mg/ml). Capsules were spread by forceps with cell layers
upward on the surface of plastic culture petri dishes. Complete
DMEM containing 15% fetal bovine serum was added. The
growth of explants culture was monitored routinely. For sub-
cultivating, monolayer of culture was incubated with trypsin
(Gibco), and the dissociated cells were split as described earlier
[59]. LECs obtained from 1 to 3 passages were used for the
experiments.
This study, classified as Research Involving Left-Over (Excess) Human
Biological Material, was approved by the ethics committee of the
University of Nebraska Medical Center (Institutional Review
Board [IRB] Approval ID: 247-09-NH). This study adhered to the
tenets of the Declaration of Helsinki (2004).
Drosophila SL2 cells (CRL-1963) were purchased from American
Type Culture Collection (Rockville, MD) and were maintained at
room temperature in Schneider cell culture medium (Invitrogen,
Carlsbad, CA) supplemented with 10% FBS and penicillin-
streptomycin.
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Total RNA was isolated using the single-step guanidine
thiocyanate/phenol/chloroform extraction method (Trizol Re-
agent; Invitrogen) and was converted to cDNA using Superscript
II RNAase H
2Reverse Transcriptase. Quantitative real-time PCR
was performed with SYBR Green Master Mix (Roche Diagnostic
Corporation, Indianapolis, IN) in a RocheH LC480 Sequence
detector system (Roche Diagnostic Corporation). The comparative
Cp method was used to calculate relative fold expression levels
using Lightcycler H 480 software, release 1.5.0 SP3. The Cps of
target genes was normalized to b-actin as an endogenous control
in each group. PCR conditions consisted of 10-min hot start at
95uC, followed by 45 cycles of 10 s at 95uC, 30 s at 60uC, and 10 s
at 72uC. Primer sequence as follows: LEDGF/p75: Forward
primer: 59-CAGCAACAGCATCTGTTAATCTAAA-39 and Re-
verse primer: 59-GGGCTGTTTTACCATTTTGG-39; Sp1: For-
ward primer: 59-CCTGGATGAGGCACTTCTGT-39 and Re-
verse primer: 59-GCCTGGGCTTCAAGGATT-39, b-actin:
Forward primer: 59-CCAACCGCGAGAAGATGA-39 and Re-
verse primer: 59-CCAGAGGCGTACAGGGATAG-39.
Expression constructs and transfections
Expression constructs, pCMV-Sp1, pPac-Sp1 and empty
vectors (pCMV-V, pPac-V) were purchased from Addgene
(Cambridge, USA). A construct containing a green fluorescent
protein (GFP) and LEDGF/p75 cDNA was generated with the
‘‘living color system’’ (Clontech, Palo Alto, CA) using the plasmid
vector pEGFP-C1 (Clontech). Similarly, full-length of Sumo1
cDNA was subcloned into pEGFP-C1 vector. The coding region
of Sumo1 was amplified by PCR from human lens cDNA library
using forward primer (59-CCGTCGACATGTCTGACCAG-
GAG-39) and reverse primer (59-TCGGATCCGTTTTGAA-
CACCACA-39) with restriction enzyme sites, Sal I and Bam HI.
The PCR product was digested and ligated into pEGFP vector.
pFLAG-Senp1 was a generous gift from Dr. Yeh, University of
Texas MD Anderson Cancer Center, Houston, TX. All transfec-
tion experiments were carried out either with Superfactamine
Reagent (Qiagen) or Neon Transfection System (Invitrogen).
Preparation of small interfering RNAs and transfection
The LEDGF/p75-specific small interfering (si)RNA expression
plasmid was designed according to the method described earlier
[41]. The sequence was selected from location 1340–1360 (59-
AAAGACAGCATGAGGAAGCGA-39). The sense and antisense
oligonucleotides with the internal loop were synthesized by
Invitrogen. These were annealed and ligated into the Bam HI
and HindIII sites of pSilencer 4.1-CMV hygro (Ambion). pSilencer
4.1- pCMVhygro expressing a scrambled siRNA (Ambion) was
used as a control. One day after transfection, cells were subjected
to a selection procedure using 400 mg hygromycine/ml over a
period of 9 days with intermittent exposure. Knockdown of
LEDGF/p75 was confirmed through Western analysis.
Sp1 knockdown using Sp1 shRNA Plasmid (h)
Sp1 expression in human lens epithelial cells was silenced with
Sp1 shRNA Plasmid (h) (Santa Cruz Biotechnology). Transfections
were carried out with Neon transfection system (Invitrogen). Cell
lysates were prepared 72 h after transfection, and silencing of Sp1
was confirmed through Western analysis. For selection of stably
transfected cells, cells were treated with puromycin (5 mg/ml).
After 3 days medium was replaced with freshly prepared selective
media. 10 days later cells were washed with PBS (7.2) and cell
lysate were submitted the western analysis and the association
between levels of LEDGF/p75 and Sp1 protein expression was
analyzed using Western analysis. shRNA (scrambled) was used as
control.
Preparation of LEDGF/p75 promoter-CAT construct
The genomic human phagemid P1 clone (Genomic System, St.
Louis, MO) was used to construct 59 flanking region of human
LEDGF/p75 gene as reported previously [20]. The genomic P1
clone comprising the LEDGF/p75 gene was subjected to Genomic
PCR with primers containing Mlu I and Nhe I, and a fragment
encompassing 21239 and +35 bp was ligated to basic pCAT
vector (Promega, Madison, WI) with the appropriate restriction
enzymes as reported earlier [20]. Similarly, deletion constructs of
different sizes (Fig. 3A, constructs: A, 2170, B; 2127, C; 263, D;
228 to +35) of LEDGF/p75 promoter were prepared with
appropriate sense primers bearing Sac Io rMlu I and antisense
with Nhe I and ligated into pCAT-Basic vector. The plasmid was
amplified using the standard method and was used for CAT assay.
To accurately locate the promoter region of human LEDGF/
p75 gene, we determined the transcription start site by the primer
extension method. Briefly, the avian myeloblastosis virus (AMV)
reverse transcriptase primer extension system (Promega) was used
with poly (A)+RNA (50 mg) as template. RNA from hLECs was
incubated with antisense oligonucleotide probe (59-
GTGGCTCCGAAGCGGATTTTCTGG-39), and was end-la-
beled with T4 polynucleotide kinase (promega) and [Y-
32p] ATP.
The RNA was hybridized with Poly(A)+ RNA, and cDNA was
synthesized following the company’s protocol. Products were then
heated for 10 min at 90uC in formamide loading buffer and
analyzed on sequencing gel to determine the size and nucleotide
base(s) of TSS. The fmol DNA Cycle Sequencing System
(Promega) was used for sequencing reactions with the primers to
read the position of extended product, and TSS was determined.
Site-directed Mutagenesis (SDM)
PCR-based site-directed mutagenesis was performed using the
QuickchangeTM Site-directed Mutagenesis kit (Stratagene, La
Jolla, CA) following the company’s protocol. We made mutations
in Sp1 binding sites (Mut-1: GC changed to TT or CG changed to
AA; Mut-2: CC changed to TA or GG changed to TA; Mut- 3:
GC changed to TT or CG changed to AA). Briefly, the double-
stranded LEDGF/p75 promoter construct (2170/+35) was used as
template DNA with a pair of complementary primers used to
mutate the LEDGF/p75 promoter construct with PCR. The










Transfection and Chloramphenicol Acetyltransferase
Assay (CAT Assay)
CAT assay was carried out using a CAT-ELISA (Roche
Diagnostics) kit. hLECs and Cos7 cells were cultured at a density
of 5610
5 cells in 5 ml of DMEM containing 15% FBS per 60-mm
petri dish in a 37uC incubator containing 5% CO2. Cells were
washed with the same medium and transfected/cotransfected with
Superfactamine Reagent (Invitrogen) with promoter/CAT report-
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SiRNA construct specific to LEDGF/p75 or Sp1 along with 1 mg
of pSEAP vector [57]. After 72 h of incubation, cells were
harvested, and extract was prepared and protein concentration
was normalized. CAT-ELISA was performed to monitor CAT
activity. The absorbance was measured at 405 nm using a micro
titer plate ELISA reader. The concentration of Plasmid DNA was
equal in each transfection to maintain the similar DNA burden on
cells and to avoid any nonspecific effect(s). Transactivation
activities were adjusted for transfection efficiencies using SEAP
values (OD; ex/em, 360/449).
Preparation of Lens Epithelial Cell Nuclear Extract
Human LEC nuclear extract was prepared as described earlier
[5,20]. Briefly, human LECs (1610
6) were cultured in 100-mm
plates. The cells were washed gently with chilled phosphate-
buffered saline (pH 7.2). Cells were collected by centrifugation
using a microcentrifuge and resuspended in 5 pellet volumes of
cytoplasmic extract buffer (10 mM HEPES, 60 mM KCl, 1 mM
EDTA, 0.075% (v/v) Nonidet P-40, 1 mM phenylmethylsulfonyl
fluoride, adjusted to pH 7.6). After a short incubation on ice, the
cytoplasmic extract was removed from the pellet. Following
washing with cytoplasmic extract without detergent (Nonidet P-
40), the fragile nuclei were resuspended in nuclear extract buffer
(20 mM Tris-HCl, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mm
EDTA, 1 mM phenylmethylsulfonyl fluoride, and 25% (v/v)
glycerol, adjusted to pH 8.0). Salt concentration was adjusted to
400 mM using 5 M NaCl, and the extract was incubated on ice
for 10 min with occasional vortexing. Finally, the extract was spun
at 14,000 rpm for 30 min to pellet the nuclei. Protein was
estimated according to the Bradford method, and extract was used
for EMSA.
Western blot and antibodies
Total cell lysates were prepared in ice-cold radio immunopre-
cipitation assay (RIPA) lysis buffer, as described previously [19].
Equal amounts of protein samples were resolved onto a 10% SDS
gel, blotted onto PVDF membrane (Perkin Elmer, Waltham, MA),
and immunostained with primary antibodies at the appropriate
dilutions of LEDGF/p75 monoclonal antibody (BD Biosciences,
USA), and Sp1 monoclonal antibody (Santa Cruz Biotechnology).
Membranes were incubated with horseradish peroxidase-conju-
gated secondary antibodies (1:1500). Specific protein bands were
visualized by incubating the membrane with luminol reagent
(Santa Cruz Biotechnology) and recorded with FUJIFILM-LAS-
4000 luminescent image analyzer (FUJIFILM Medical System Inc,
USA). To ascertain comparative expression and equal loading of
the protein samples, the membrane stained earlier was stripped
and reprobed with b-actin antibody (Abcam, USA).
Electrophoretic Mobility Shift Assay (EMSA)
To perform gel-shift assay, oligonucleotides containing Sp1
binding elements and respective mutant probes were synthesized
commercially, annealed, and end-labeled with [c-
32P] ATP using
T4 polynucleotide kinase (New England Biolabs, Inc.). The
binding reaction was performed in 20 ml of binding buffer
containing 20 mM Tris-HCl (pH 8.0), 75 mM KCl, 5% glycerol,
50 mg/ml bovine serum albumin, 0.025% Nonidet P-40, 1 mM
EDTA, 5 mM DTT, and 1 mg of poly (dI/dC). Five fmol
(1000 cpm) of the end-labeled probe were incubated on ice for
30 min with 10–1000 ng of the GST-LEDGF/p75 fusion protein.
Samples were then loaded on 5% polyacrylamide gel in 0.56TBE
buffer for 2 h at 10 V/cm. The gel was dried and autoradio-
graphed.
Chromatin Immunoprecipitation (ChIP) Analysis
ChIP analysis was conducted by the ChIP-IT express kit (Active
Motif). Cells were processed following the company’s protocol.
The fixation reactions were stopped by adding Glycine Fix-Stop
solution. After washing with ice-cold PBS, cells were collected in
solution containing PMSF, and centrifuged at 4uC. Cell pellet was
disrupted with a Dounce homogenizer (10 strokes of 10 s each to
aid in nuclei release) in 1 ml ice-cold lysis buffer containing
protease inhibitor and PMSF. After centrifugation, nuclei were
resuspended in shearing buffer (Active Motif) and incubated on ice
for 10 min. Chromatin was then sheared to 200–300 bp using a
closed system ultrasonic cell disruptor (Microson, Farmingdale,
NY). Samples were centrifuged at 15,000 rpm for 10 min at 4uC,
and the supernatant was stored at 280uC. An aliquot of this
material was retained as ‘‘input’’ DNA. The remaining chromatin
sample was divided; one-half was immunoprecipitated with the
test antibody (Sp1+ ChIP grade antibody, Millipore), and the
second half was used for a mock immunoprecipitation with a
control IgG. ChIP assay bands were compared with assay bands
obtained with the input DNA. Mock immunoprecipitation
reactions were performed using control IgG (ChIP-IT Control
Kit, Active Motif). Regions of the human LEDGF/p75 promoter
that contained Sp1 binding sites were amplified (Go-Taq,
Promega) using specific primers. For comparison, a 222-bp
sequence from the human LEDGF/p75 promoter beyond 2 kb
Sp1 binding site was also amplified from the IP and mock IP
samples. Sequences of primers used in this experiment are shown
in Fig. 5. ChIP assays were conducted via standard PCR
amplification (Go-Taq) and agarose gel electrophoresis. Amplified
DNA bands were resolved on 2.5% agarose gels, and images were
obtained using FUJIFILM-LAS-4000 luminescent image analyzer
(FUJIFILM Medical system Inc, USA). PCR band sizes were
verified using a low molecular mass DNA ladder (Fermentas).
Cell survival assay (MTS assay)
A colorimetric MTS assay (Promega, Madison, MI, USA) was
performed as described earlier. This assay of cellular proliferation
uses 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2
to 4-sulfophenyl)-2H-tetrazolium salt. Upon being added to
medium containing viable cells, MTS is reduced to a water-
soluble formazan salt. The O.D. 490 nm values were measured
after 4 h with an ELISA reader.
Statistical method
Data are presented as Mean 6 S.D. of the indicated number of
experiments. Data were analyzed by Student’s t-test. A p value of
,0.01 and ,0.001 was defined as indicating a statistically
significant difference.
Supporting Information
Figure S1 Determination of the transcription start site
of the LEDGF/p75 gene by primer extension. Transcrip-
tion start site was determined with primer extension analysis using
commercial kit (Promega). The 59-radiolabelled antisense nucle-
otide 59-GAGGCACCGAAGCGGATTTTCTGG-39 comple-
mentary to human LEDGF/p75 cDNA sequence was used as
primer in a reverse transcription reaction with control E. coli tRNA
(lane 1), and poly (A)+ RNA (lane 2) isolated from human LECs.
Products obtained were resolved on 8% denaturating sequencing
gel and subjected to autoradiography. M (lane 10): molecular
weight markers. The arrow corresponds to the band at position
125(nt) size is the major transcription start site (TSS), and two
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and T sequences respectively used to determine start sites.
(TIF)
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